Bavarian Nordic Repurchases Shares Under DKK 250M Buyback Plan
Bavarian Nordic is buying back shares worth up to DKK 250 million between Sept. 1 and Oct. 30, 2026, under EU market-abuse safe harbor rules.
Danish biotechnology company Bavarian Nordic A/S has disclosed transactions carried out under a share buyback program it launched Sept. 1, 2026, according to a filing released Monday on the Nasdaq Copenhagen exchange under the ticker BAVA.
The program authorizes the company to repurchase its own shares for a total value of up to DKK 250 million over a two-month window running through Oct. 30, 2026. Share buybacks of this scale are typically used by companies to return capital to shareholders, reduce the share count, or signal confidence in the firm's financial position — though the company did not specify its rationale in the announcement.
Read more OTCX Integrates OTC Derivatives Trading Into BlackRock Aladdin →
The repurchases are being conducted in compliance with Regulation (EU) No. 596/2014, the European Union's Market Abuse Regulation, as well as Commission Delegated Regulation (EU) 2016/1052. Together, those rules form the so-called Safe Harbour Regulation, a legal framework that shields companies from market manipulation allegations when buybacks meet prescribed conditions on timing, volume, and price.
Bavarian Nordic, headquartered in Copenhagen, is a vaccine-focused biopharmaceutical company known for its work in infectious disease and oncology immunology. The company's adherence to EU safe harbor provisions reflects standard practice for listed European firms conducting programmatic share repurchases on regulated markets.
Continue reading at GlobeNewswire - Industry News on Financial Services.
